SubQ Velcade and Seebri Breezhaler get EC OK
This article was originally published in Scrip
Executive Summary
Novartis/ Vectura's once-daily long-acting muscarinic antagonist (LAMA) Seebri Breezhaler (50mcg glycopyrronium bromide, previously NVA237) and Janssen's subcutaneous Velcade (bortezomib) have received marketing approvals in Europe.